Also, we recorded whether this treatment was withdrawn. The routine

practice in our stroke unit is to administer statins as soon as possible to every patients with ischemic stroke, and this treatment is usually indefinite; stroke etiological subtype, according to the SSS-TOAST classification (Ay et al. 2005); Inhibitors,research,lifescience,medical severity of the neurological deficit at admission (NIHSS score); mortality and functional outcome at 3 months. A favorable outcome was sellectchem defined as a score 0–2 on the Rankin scale score. Statistical analyses As we found many patients with a complete absence of EPC, we compared patients with (EPC+) and without EPC (EPC−). We combined patients with 1 or more EPC in the same EPC+ group. Using this dichotomized variable, we compared categorical Enzalutamide pancreatic cancer variables with contingency tables and the Chi square test, and compared means and standard Inhibitors,research,lifescience,medical deviation of quantitative variables with the Student’s t-test. NIHSS scores were compared with the Mann–Whitney U test. The time course of EPC counts Inhibitors,research,lifescience,medical was assessed with the analysis of variance (ANOVA) for repeated measures and the Greenhouse-Geisser test and confirmed with the nonparametric Friedman test. For most analyses, EPC

counts were analyzed also as a continuous variable with nonparametric tests, as they did not follow a normal distribution (Mann–Whitney U test and Spearman’s correlation were used). To study the Inhibitors,research,lifescience,medical association of variables with EPC counts, a stepwise forward logistic regression analysis was performed by

selecting variables with a P-value ≤ 0.1 Inhibitors,research,lifescience,medical in the bivariate analyses and by considering the EPC count as the dependent variable. All the analyses for the samples obtained at the acute (within 48 h), subacute (7 days), and chronic (3 months) stages were repeated. A similar approach was used to assess the prognostic value of EPC counts, with favorable outcome (Rankin 0–2) as the dependent variable. Results From a total of 165 patients evaluated at baseline, 19 were excluded due to a diagnosis other than stroke, Batimastat resulting in a final sample of 146 patients. The number of patients studied at day 7 was 121; no sample was available from the remaining due to death (n = 6), early discharge (n = 4), withdrawal of consent (n = 1), and defective blood sampling (n = 14). At the 3-month follow-up, we obtained a blood sample from 92 patients and we failed to collect a blood sample from 54 patients due to death (n = 9), withdrawal of consent (n = 1), information on functional outcome obtained by telephone (n = 21), defective blood sampling (n = 20), and unknown (n = 3).